This training includes an overview of the mechanism of action of immune checkpoint inhibitors (ICIs), associated dermatologic immune-related adverse events (irAEs), and when to refer patients to their oncologist for assessment and management of symptoms consistent with irAEs.
At the completion of this application-based activity, participants will be able to:
- Describe the mechanism of action of immune checkpoint inhibitors.
- Categorize the seven Food and Drug Administration–approved immune checkpoint inhibitors as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitors, programmed death-1 (PD-1) inhibitors, or programmed death-ligand 1 (PD-L1) inhibitors.
- Recognize the presenting symptoms of the most common dermatologic immune-related adverse events in patients treated with immune checkpoint inhibitors.
- Identify the best questions to ask patients with cancer to determine the symptoms and severity of a potential dermatologic immune-related adverse event.
- Discuss when and how to refer patients to their medical oncologist for further work-up.
Activity type: Knowledge-based
Target Audience: Pharmacists
Learning Level: 2
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The following activity is not approved for CPE credit.
To complete Immune Checkpoint Inhibitors & Dermatologic Toxicities: Key Points for the Community Pharmacist, participants will need to complete the activity and evaluation questions. Participants need to have a valid pharmacist.com username and password.
Immune Checkpoint Inhibitors & Dermatologic Toxicities: Key Points for the Community Pharmacist is an activity developed by the American Pharmacists Association.
Lisa Cordes, PharmD, BCACP, BCOP, and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures.
Conflicts of interest have been resolved through content review by Helen Sairany, BA, PharmD, MBA, BCACP, Director of Content Development & Partnership at the American Pharmacists Association.
There is no fee associated with this activity.
Computer and internet access are required to complete this activity. Please visit our website to view the Technology System Requirements in order to have a positive learning experience.